Advertisement
Advertisement
GOSS
Gossamer Bio, Inc. Common Stock
9.77
USDSponsored
+0.35
+3.72%
Nov 06, 15:59 UTC -5
Closed
After-Market
9.37
-0.40
-4.15%
Gossamer Bio, Inc. Common Stock (GOSS) Earnings
GOSS Earnings Reports
Positive Surprise Ratio
GOSS beat 15 of 31 last estimates.
48%
Next Report
Date of Next Report
Mar 15, 2027
Estimate for Q4 26 (Revenue/ EPS)
$3.59M
/-$3.83
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
-74.01%
/-77.20%
Gossamer Bio, Inc. Common Stock earnings per share and revenue
On Nov 06, 2026, GOSS reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of -3.86 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 12.39 million, with a --% difference. The market reacted with a -1.80% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of -3.83 USD, with revenue projected to reach 3.59 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Immunocore Holdings plc - ADR
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.13
Actual
-$0.28
Surprise
-104.08%
Entera Bio Ltd. Ordinary Shares
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.06
Actual
-$0.11
Surprise
-58.50%
Vogenx Inc Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.47
Surprise
-187.99%
Agenus Inc.
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.27
Actual
$0.02
Surprise
+107.26%
Anika Therapeutics Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
$0.06
Actual
-$0.02
Surprise
-132.68%
Moderna, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$1.27
Actual
$0.38
Surprise
+129.79%
Bio-Techne Corp.
Report Date
Nov 06, 2026 For Q1 27
Estimate
$0.44
Actual
$0.44
Surprise
-1.96%
Aligos Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$2.21
Actual
-$2.09
Surprise
+5.58%
CervoMed Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.49
Actual
-$0.39
Surprise
+21.97%
Creative Medical Technology Holdings, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.40
Surprise
-63.40%
FAQ
What were Gossamer Bio, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Gossamer Bio, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Gossamer Bio, Inc. Common Stock's Q3 2026 earnings?
The stock price moved down -1.8%, changed from $9.45 before the earnings release to $9.28 the day after.
When is Gossamer Bio, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 15, 2027.
What are the forecasts for Gossamer Bio, Inc. Common Stock's next earnings report?
Based on --
analysts, Gossamer Bio, Inc. Common Stock is expected to report EPS of -$3.83 and revenue of $3.59M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.